Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics Assessement Report 2024 (Updated)

DelveInsight's, "Fibrodysplasia ossificans progressive Pipeline Insight 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Fibrodysplasia ossificans progressiva pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Fibrodysplasia Ossificans Progressiva Research. Learn more about our innovative pipeline today! @ Fibrodysplasia Ossificans Progressiva Pipeline Outlook- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Fibrodysplasia Ossificans Progressiva Pipeline Report
• In November 2024:- Ashibio Inc.- This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP.
• In November 2024:- Regeneron Pharmaceuticals- This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP.
• In November 2024:- Clementia Pharmaceuticals Inc.- A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head.
• DelveInsight's Fibrodysplasia Ossificans Progressiva pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Fibrodysplasia Ossificans Progressiva treatment.
• The leading Fibrodysplasia Ossificans Progressiva Companies such as Regeneron Pharmaceuticals, Ipsen, Incyte Corporation, and others.
• Promising Fibrodysplasia Ossificans Progressiva Therapies such as Andecaliximab, Garetosmab, IPN60130, AZD0530 Difumarate, and others.

Stay informed about the cutting-edge advancements in Fibrodysplasia Ossificans Progressiva treatments. Download for updates and be a part of the revolution in care @ Fibrodysplasia Ossificans Progressiva Clinical Trials Assessment- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fibrodysplasia Ossificans Progressiva Emerging Drugs Profile

• REGN2477: Regeneron Pharmaceuticals
REGN2477 (also known as garetosmab) is an antibody that binds to Activin A and blocks its activity. By binding and blocking Activin A, REN2477 prevents the formation and growth of HO in FOP. REGN2477 has received Orphan Drug status for FOP from the US Food and Drug Administration (FDA), and orphan status for the treatment of FOP in the EU. Currently, the drug is being evaluated in the Phase III clinical trial for the treatment of Fibrodysplasia ossificans progressive.

• IPN60130: Ipsen
IPN60130 (Fidrisertib) is an oral investigational drug designed to selectively target the mutant FOP receptor (ACVR1/ALK2), the underlying cause of FOP. FDA has granted Fast Track Designation to IPN60130 for the treatment of FOP. Currently, the drug is being evaluated in the Phase II clinical trial for the treatment of Fibrodysplasia ossificans progressive.

Learn more about Fibrodysplasia Ossificans Progressiva Drugs opportunities in our groundbreaking Fibrodysplasia Ossificans Progressiva Research and development projects @ Fibrodysplasia Ossificans Progressiva Unmet Needs- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fibrodysplasia Ossificans Progressiva Companies
Regeneron Pharmaceuticals, Ipsen, Incyte Corporation, and others.

Fibrodysplasia ossificans progressiva pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Fibrodysplasia Ossificans Progressiva Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Product Type

Discover the latest advancements in Fibrodysplasia Ossificans Progressiva treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Fibrodysplasia Ossificans Progressiva Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Fibrodysplasia Ossificans Progressiva Pipeline Report
• Coverage- Global
• Fibrodysplasia Ossificans Progressiva Companies- Regeneron Pharmaceuticals, Ipsen, Incyte Corporation, and others.
• Fibrodysplasia Ossificans Progressiva Therapies- Andecaliximab, Garetosmab, IPN60130, AZD0530 Difumarate, and others.
• Fibrodysplasia Ossificans Progressiva Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Fibrodysplasia Ossificans Progressiva Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Fibrodysplasia Ossificans Progressiva Pipeline on our website @ Fibrodysplasia Ossificans Progressiva Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Fibrodysplasia ossificans progressiva: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fibrodysplasia ossificans progressiva- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. REGN2477: Regeneron Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IPN60130: Ipsen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Fibrodysplasia ossificans progressiva Key Companies
21. Fibrodysplasia ossificans progressiva Key Products
22. Fibrodysplasia ossificans progressiva- Unmet Needs
23. Fibrodysplasia ossificans progressiva- Market Drivers and Barriers
24. Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion
25. Fibrodysplasia ossificans progressiva Analyst Views
26. Fibrodysplasia ossificans progressiva Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.